Slide 1: Exchange filing cover letter: Presentation of Q2 FY25 Earnings Call
Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com BIO/SECL/SG/2024-25/116 October 30, 2024 To, To, The Secretary The Secretary BSE Limited National Stock Exchange of India Limited Department of C
Slide 2: Biocon Limited Q2 FY25 Earnings Call
Biocon Limited Q2 FY25 Earnings Call 30 - OCTOBER- 2 0 2 4 The Multiplier Effect MAXIMIZING VALUE
Slide 3: Safe Harbor Statement
Safe Harbor Statement Certain statements made during the call concerning the future growth prospects of the Company may be forward-looking statements, which are subject to number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in s
Slide 4: Group CEO Opening Remarks
Group CEO Opening Remarks
Slide 5: Opening Remarks: Q2 FY25 Performance Overview
Opening Remarks: Q2 FY25 Performance Overview Overall performance relatively muted but in-line with expectations Healthy double-digit revenue growth in Biosimilars, continued pressures in Generics and a marginal decline in Research Services revenues on a Y-o-Y basis Maintain our outlook for a transi
Slide 6: Financial Highlights
Financial Highlights
Slide 7: Financial Highlights – Q2 FY25
Financial Highlights – Q2 FY25 In ₹ Cr Q2 FY25 Q2 FY24 Q1 FY25 YoY% QoQ% Generics 624 676 659 (8) (5) Biosimilars 2,182 1,969 2,083 11 5 Research Services 891 910 790 (2) 13 Revenue from Operations 3,590 3,462 3,433 42 52 Total Revenue 3,623 3,620 4,567 0%1 (21)1 Core EBITDA3 992 1,100 903 (10) 10 %
Slide 8: Generics
Generics
Slide 9: Biocon Generics: Q2 FY25 Business Performance update
Biocon Generics: Q2 FY25 Business Performance update Q2 Q2 Q1 Demand and pricing challenges coupled with a planned facility shutdown In ₹ Cr YoY% QoQ% FY25 FY24 FY25 impacted performance Revenue from 624 676 659 (8) (5) Signed exclusive licensing agreement with two leading pharmaceutical Operations
Slide 10: Biosimilars
Biosimilars
Slide 11: Biocon Biologics: Q2 FY25 Business Performance Update
Biocon Biologics: Q2 FY25 Business Performance Update Strong performance in the US, with market shares at ~20% for the oncology portfolio and in the mid-to high-teens for the insulin franchise Market shares in Europe remain largely stable with a strong performance in key markets e.g. bAdalimumab is
Slide 12: Biocon Biologics: Q2 FY25 Financial Performance Update
Biocon Biologics: Q2 FY25 Financial Performance Update Financial Performance Q2 Q2 Q1 In ₹ Cr YoY% QoQ% FY25 FY24 FY25 Revenue grew 19% vs. last year on a like-to-like basis Revenue from 2,182 1,9691 2,083 11 5 Operations EBITDA Margin after adjusting for forex loss due to JPY volatility remains hea
Slide 13: Biocon Biologics: Q2 FY25 Regulatory Update
Biocon Biologics: Q2 FY25 Regulatory Update Site Inspections US FDA has classified Biocon Biologics' Drug Substance facility at Biocon Campus (Site 1), Bengaluru as Voluntary Action Initiated (VAI) US FDA conducted a cGMP inspection of Malaysia facility; Company has submitted a comprehensive CAPA pl
Slide 14: Research Services
Research Services
Slide 15: Syngene: Q2 FY25 update
Syngene: Q2 FY25 update Performance for Q2 in-line with expectations and previous guidance Positive signs of recovery in Discovery Services, largely driven by pilot projects from large and mid-sized biopharma clients; sustained Q2 Q2 Q1 In ₹ Cr YoY% QoQ% performance from Dedicated Centres FY25 FY24
Slide 16: Novels
Novels
Slide 17: Novels: Bicara Therapeutics IPO
Novels: Bicara Therapeutics# IPO In September 24, Bicara Therapeutics IPO was well received by investors with Bicara raising USD 362 million Post Bicara’s IPO, as of September 30th, 2024, Biocon shareholding in Bicara at 10.7% # a US based clinical-stage biotechnology company. Post Q3 FY24, pursuant
Slide 18: Concluding Remarks
Ne me : Concluding Rem Ya \ a | ay fo ‘ = es > ae % goth o - 4 : ~ 4 aa < i : ‘ in
Slide 19: Concluding Remarks: Q2 FY25
Concluding Remarks: Q2 FY25 Financial performance for Q2/H1 FY25 relatively muted Expect an improved H2; maintain guidance of transition to accelerated growth underpinned by - Continued recovery in Syngene Good momentum in Biosimilars New product launches in Generics
Slide 20: Q&A
Q&A The Multiplier Effect MAXIMIZING VALUE